[go: up one dir, main page]

MX2022014533A - Metodo para seleccionar proteinas recombinantes ricas en m6p. - Google Patents

Metodo para seleccionar proteinas recombinantes ricas en m6p.

Info

Publication number
MX2022014533A
MX2022014533A MX2022014533A MX2022014533A MX2022014533A MX 2022014533 A MX2022014533 A MX 2022014533A MX 2022014533 A MX2022014533 A MX 2022014533A MX 2022014533 A MX2022014533 A MX 2022014533A MX 2022014533 A MX2022014533 A MX 2022014533A
Authority
MX
Mexico
Prior art keywords
recombinant human
selection
human lysosomal
recombinant proteins
lysosomal proteins
Prior art date
Application number
MX2022014533A
Other languages
English (en)
Inventor
Russell Gotschall
Hung V Do
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2022014533A publication Critical patent/MX2022014533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Water Supply & Treatment (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para producir, capturar y purificar proteínas lisosomales humanas recombinantes. Estas proteínas lisosomales humanas recombinantes pueden tener un contenido elevado de residuos de manosa-6-fosfato. Composiciones farmacéuticas que comprenden estas proteínas lisosomales humanas recombinantes. Métodos de tratamiento. Usos de estas proteínas lisosomales humanas recombinantes.
MX2022014533A 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p. MX2022014533A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662315400P 2016-03-30 2016-03-30
US201762457584P 2017-02-10 2017-02-10
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins

Publications (1)

Publication Number Publication Date
MX2022014533A true MX2022014533A (es) 2022-12-13

Family

ID=58640993

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018011951A MX2018011951A (es) 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018011951A MX2018011951A (es) 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Country Status (12)

Country Link
US (3) US10227577B2 (es)
JP (3) JP7046003B2 (es)
KR (4) KR102455821B1 (es)
AU (3) AU2017239640B2 (es)
CA (1) CA3019354A1 (es)
CL (1) CL2018002767A1 (es)
IL (3) IL262060B (es)
MX (3) MX2018011951A (es)
PE (1) PE20190127A1 (es)
SG (1) SG11201808592PA (es)
WO (1) WO2017173059A1 (es)
ZA (2) ZA201807184B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
KR20250017756A (ko) * 2016-03-30 2025-02-04 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
MX2018011951A (es) * 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
TW201829770A (zh) * 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
HRP20230576T1 (hr) * 2017-05-15 2023-09-01 Amicus Therapeutics, Inc. Rekombinantna ljudska kisela alfa-glukozidaza
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
GB201911686D0 (en) * 2019-08-15 2019-10-02 Fujifilm Diosynth Biotechnologies Uk Ltd Process for purifying target substances
WO2021046443A1 (en) * 2019-09-06 2021-03-11 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
WO2021122943A1 (en) * 2019-12-17 2021-06-24 Navigo Proteins Gmbh Binding proteins for the enzyme acid alpha glucosidase (gaa) and uses thereof
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
WO2021257409A1 (en) 2020-06-14 2021-12-23 Genzyme Corporation Compositions and methods for treating late-onset pompe disease
US20250134967A1 (en) * 2022-02-07 2025-05-01 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
AU2023265155A1 (en) * 2022-05-05 2024-12-12 Amicus Therapeutics, Inc. Methods for treating pompe disease
EP4626465A1 (en) 2022-12-02 2025-10-08 Amicus Therapeutics, Inc. Methods for treating late onset pompe disease in pediatric patients
AU2023406510A1 (en) 2022-12-02 2025-07-10 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
CA2309321A1 (en) 1997-11-10 1999-05-20 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP4990434B2 (ja) 1998-12-07 2012-08-01 ジェンザイム・コーポレーション ポンペ病の処置
WO2000047198A2 (en) 1999-02-12 2000-08-17 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
ATE234626T1 (de) 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2523024T3 (es) 2000-07-18 2014-11-20 Duke University Tratamiento de glucogenosis de tipo II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
IL158623A0 (en) 2001-04-30 2004-05-12 Symbiontics Inc Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP2005523882A (ja) 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
ES2545619T3 (es) 2003-01-31 2015-09-14 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) * 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
EP1716232B9 (en) 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
MX2007014470A (es) * 2005-05-17 2008-02-06 Amicus Therapeutics Inc Metodo para el tratamiento de enfermedad de pompe usando derivados de 1-desoxinojirimicina.
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
CA2685332A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
DK2252313T3 (en) 2008-02-12 2015-07-13 Amicus Therapeutics Inc METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES
CA2718182A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
JP2011517556A (ja) 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en) 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
HUE060974T2 (hu) 2008-12-16 2023-04-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállítására
ES2564093T3 (es) 2009-04-09 2016-03-17 Amicus Therapeutics, Inc. Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
CN104651428A (zh) * 2009-09-29 2015-05-27 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
JP6151183B2 (ja) 2010-09-29 2017-06-21 オキシレイン ユーケー リミテッド マンノース−１−ホスホ−６−マンノース結合からキャップを外すことおよびリン酸化ｎ−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法
SG194486A1 (en) 2011-04-22 2013-12-30 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CA2860085A1 (en) 2011-12-22 2013-06-27 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2013134530A1 (en) 2012-03-07 2013-09-12 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of pompe disease
JP6194324B2 (ja) 2012-03-15 2017-09-06 オキシレイン ユーケー リミテッド ポンペ病の処置のための方法および材料
US20150086530A1 (en) 2012-05-03 2015-03-26 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
KR102741048B1 (ko) * 2014-09-30 2024-12-11 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
CA3010205A1 (en) * 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
MX2018011951A (es) * 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.

Also Published As

Publication number Publication date
KR102343162B1 (ko) 2021-12-23
IL295551B2 (en) 2025-08-01
JP2019509754A (ja) 2019-04-11
PE20190127A1 (es) 2019-01-17
AU2024259782A1 (en) 2024-11-28
NZ746768A (en) 2025-05-02
KR20180128945A (ko) 2018-12-04
IL262060B (en) 2022-09-01
US20170335301A1 (en) 2017-11-23
AU2022259797B2 (en) 2024-08-08
WO2017173059A1 (en) 2017-10-05
IL262060A (en) 2018-11-29
ZA202006604B (en) 2023-04-26
JP7436545B2 (ja) 2024-02-21
US10227577B2 (en) 2019-03-12
MX2018011951A (es) 2019-02-13
KR20210157477A (ko) 2021-12-28
IL319770A (en) 2025-05-01
KR102455821B1 (ko) 2022-10-18
IL295551B1 (en) 2025-04-01
JP7046003B2 (ja) 2022-04-01
IL295551A (en) 2022-10-01
KR20220145918A (ko) 2022-10-31
CA3019354A1 (en) 2017-10-05
AU2022259797A1 (en) 2022-12-01
AU2017239640A1 (en) 2018-10-25
KR102790256B1 (ko) 2025-04-04
US20190382742A1 (en) 2019-12-19
BR112018070189A2 (pt) 2019-02-19
ZA201807184B (en) 2021-02-24
JP2024063015A (ja) 2024-05-10
AU2017239640B2 (en) 2022-07-28
KR20250050123A (ko) 2025-04-14
US11441138B2 (en) 2022-09-13
SG11201808592PA (en) 2018-10-30
MX2022014532A (es) 2022-12-13
CL2018002767A1 (es) 2019-01-11
US20230079225A1 (en) 2023-03-16
JP2022101545A (ja) 2022-07-06
NZ786723A (en) 2025-07-25

Similar Documents

Publication Publication Date Title
MX2022014533A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
PH12017501481A1 (en) Bicyclic heterocycles as fgfr inhibitors
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
MY187486A (en) Cysteine protease
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MY179105A (en) Methods of treating alzheimer's disease
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
IN2013MU03583A (es)
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
NZ728401A (en) High purity oritavancin and method of producing same
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
EP4406613A3 (en) Immunogenic arginase peptides
PH12020551618A1 (en) Erenumab compositions and uses thereof
EP4279577A3 (en) Process
EA201892185A1 (ru) Способ отбора рекомбинантных белков с высоким содержанием m6p